What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
Theranos said its technology could run a broad menu of blood tests from a few drops collected by a finger stick, using a small sample container called a nanotainer and a proprietary analyzer. Official records show a much narrower reality: the analyzer performed only a limited number of tests, had accuracy and reliability problems, and could not match conventional laboratory instruments for speed and high-volume testing. The SEC also reported that most patient tests were run on modified or standard commercial analyzers made by other companies. The gap between the promise and the equipment’s demonstrated performance is central to understanding the company’s collapse.
What Theranos claimed would happen to a blood sample
The pitch began with collection. Instead of drawing blood from a vein into several tubes, a provider could prick a patient’s finger and collect a few drops in a small container Theranos called a nanotainer. The company presented that sample as sufficient for a broad range of tests. It would then be analyzed on equipment developed by Theranos, referred to in official records as the TSPU, Edison, or miniLab.
In the proposed workflow, the small sample and the proprietary analyzer were parts of one system: collect less blood, transport or store it in the nanotainer, and run multiple tests without relying on the conventional collection process. Theranos argued that this could make testing faster, more accurate, more reliable, and less expensive. Those were claims about the system as a whole, not simply about the convenience of a finger stick.
The appeal is easy to understand. A finger-stick sample can seem less burdensome than a venous draw, and a compact analyzer suggests testing might be brought closer to where patients receive care. But collection convenience is not the same as analytical validity. A test result must be dependable for the specific measurement being made, and the process has to work across the tests, samples, and operating conditions for which it is offered. The company’s central challenge was not merely collecting a smaller sample; it was demonstrating that its system could produce reliable results across a broad clinical menu.
#1 Best Overall
What the proprietary analyzer could actually do
The available official records do not support the claim that Theranos’s analyzer was wholly nonfunctional. They describe it as capable of performing a limited number of tests. The documented problem is the mismatch between that limited capability and the breadth and performance Theranos presented to investors, patients, and business partners.
A 2026 HHS administrative board decision describes accuracy and reliability problems with the proprietary analyzer. It also says the device performed only a limited number of tests, was slower than some competing devices, and could not match conventional analyzers in high-throughput settings. In practical terms, this means the machine’s limits were not confined to a missing feature or a single inconvenient workflow. The official account points to shortcomings in the range of tests and in the dependable, rapid processing needed for a large clinical operation.
No single verified accuracy percentage or comprehensive failure rate is established by these records. It would therefore be misleading to reduce the story to a claim that the system was wrong a particular percentage of the time. Nor do the cited official summaries establish one definitive engineering cause, such as a specific calibration, dilution, or microfluidics fault. They support a conclusion about performance and deployment, not a complete assay-by-assay technical postmortem.
Claimed system and documented performance
| Dimension | Theranos’s presentation | What official records establish |
|---|---|---|
| Sample collection | A few drops from a finger stick, collected in a nanotainer rather than relying on conventional venous draws and multiple tubes. | The nanotainer-and-finger-stick workflow was part of the company’s proposed system; the cited records do not establish that this approach reliably supported the broad menu promoted. |
| Test range | A broad range of clinical blood tests using Theranos’s own technology. | The proprietary analyzer performed only a limited number of tests. The SEC said most patient tests were run on modified or standard commercial analyzers made by other manufacturers. |
| Accuracy and reliability | Theranos promoted its tests as more accurate and reliable. | HHS records identify accuracy and reliability problems. A comprehensive accuracy percentage is not stated in the cited official records. |
| Speed and capacity | The approach was presented as faster than conventional lab testing. | HHS records say the proprietary device lagged some competitors in speed and could not match conventional machines for high-throughput testing. |
The comparison is about the system’s stated ambitions and the capabilities described in official records. It does not establish that every test Theranos offered had the same performance problem, or that every result from a proprietary device was inaccurate.
Why using a few drops is not enough to prove a test works
The blood-collection idea and the testing claim are related, but they answer different questions. A finger stick can reduce the amount of blood collected from a patient. That fact alone does not show that a given analyzer can measure every requested substance accurately from that sample, or that it can do so repeatedly at the scale required by a laboratory.
For a clinical service to deliver on a broad menu, the complete path has to work: the sample must be collected and handled appropriately, the method must support the tests being offered, and results must be dependable enough for their intended use. A compact instrument may be useful for some measurements or circumstances without being a replacement for larger instruments across a high-volume laboratory. The HHS decision’s distinction between limited test capability and conventional high-throughput performance is important for that reason.
That distinction also helps avoid two opposite oversimplifications. The evidence does not say that small-volume testing is inherently impossible, nor does it establish that the Theranos device never produced a usable result. It says the proprietary analyzer’s demonstrated range and performance did not support the full story of a broadly capable, superior replacement for conventional testing.
What happened in patient testing
The SEC’s 2018 enforcement release reported that the vast majority of patient tests were actually performed on modified or standard commercial analyzers made by other companies. This fact is central to the difference between Theranos’s public image and its laboratory operations. The company was widely associated with a proprietary machine that would transform testing, but the SEC said the bulk of the patient testing relied on equipment from other manufacturers.
Free tools Windows power users keep installed
One-click scans. No signup required.
Use of commercial equipment is not, on its own, proof of wrongdoing; clinical laboratories commonly use instruments developed by manufacturers. The significance here is the contrast with the claimed operating model. If most testing depended on third-party analyzers, the proprietary platform was not doing the broad share of patient work that the public-facing story could lead people to expect. And where commercial instruments were modified, that fact does not by itself establish how any particular modification affected a result; the cited SEC summary does not supply an assay-level engineering account.
The SEC also reported that Theranos raised more than $700 million from investors and had a little more than $100,000 in operating revenue in 2014. These are business figures from the SEC’s 2018 release, not measurements of assay accuracy, throughput, or clinical performance. They help describe the scale of the company’s representations and financing, but they should not be mistaken for technical evidence about a particular test.
Why the Walgreens rollout stalled
Theranos sought to put its testing service into retail locations, making the idea of convenient finger-stick testing visible to consumers. The 2026 HHS board decision says the Walgreens rollout stalled amid performance concerns and summarizes evidence that the proprietary device could not match conventional analyzers in high-throughput settings.
A retail location might make sample collection more convenient, but it does not remove the laboratory requirements behind a result. A service still needs a test menu the equipment can reliably perform, sufficient capacity for demand, and results that meet appropriate standards. If an analyzer has limited range or reliability problems, expansion can magnify rather than solve those constraints: more locations and more patients increase operational demands without making the underlying system more capable.
Outdated Drivers Are Slowing You Down
One free scan finds every outdated or missing driver and matches the right update for your exact hardware.Free scan · exact hardware matchPC Slower Than It Used to Be?
A free scan shows the junk files, broken settings and background clutter dragging Windows down - then fixes them in one click.Free scan · Windows 10 & 11The official record supports performance concerns as a reason the rollout stalled. It does not, in the cited summary, provide a complete chronology of every commercial decision or identify a single event that stopped the expansion. The defensible conclusion is narrower: the retail ambition encountered a practical limit in the capabilities of the proprietary technology.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.How technology claims became a legal issue
Prosecutors alleged that Theranos founder Elizabeth Holmes and former president Ramesh “Sunny” Balwani knowingly made false or misleading claims about the technology’s accuracy, reliability, speed, affordability, and limitations. The Justice Department’s case summary identifies claims involving tests such as calcium, chloride, potassium, bicarbonate, HIV, HbA1c, hCG, and sodium. Those named tests illustrate the breadth of the allegations; they should not be read as a finding that every named test had an identical problem.
Rank #3
- Brand New in box. The product ships with all relevant accessories
It is important to distinguish those allegations from what juries decided. Holmes was convicted on investor-related fraud counts and acquitted on patient-related counts. Jurors did not reach unanimous verdicts on three additional investor counts. Balwani’s separate criminal case resulted in convictions that included patient-related fraud. These outcomes do not mean that Holmes was convicted of defrauding patients, and the different results in the two cases should not be collapsed into a single verdict.
The SEC’s civil enforcement matter is another distinct track. Its 2018 release described allegations against Theranos and Holmes and a resolution in which they neither admitted nor denied those allegations. A civil settlement or enforcement resolution is not the same thing as a criminal conviction after a jury trial. Keeping these legal categories separate makes the story more accurate: the SEC described alleged investor deception; prosecutors brought criminal charges; and juries returned specific verdicts for each defendant and each set of counts.
Quick wins for a faster PC:
Scan for outdated or missing drivers - takes under a minuteDriver Scan →Repair Windows errors before they cause bigger problemsFix Now →The central reason Theranos’s promise failed
The strongest conclusion supported by the official records is that the public promise exceeded the proprietary analyzer’s demonstrated capabilities. Theranos described a broad, fast, accurate, and reliable testing system built around tiny finger-stick samples. HHS records describe a machine with a limited test range, accuracy and reliability problems, and weaker speed and throughput than conventional alternatives in relevant settings. Meanwhile, the SEC said most patient tests were performed on modified or standard commercial analyzers.
That combination created a gap at three levels. First, the device did not demonstrate the breadth and performance implied by the claims. Second, the actual testing operation relied heavily on equipment other than the proprietary system at the center of the company’s story. Third, the ambition to offer convenient retail testing required dependable performance at a scale the proprietary analyzer could not match, according to the HHS account of the stalled rollout.
This explanation is more precise than saying simply that “the machine did not work.” The official records describe limited function as well as serious limitations; they do not give a complete technical account of every assay or explain the failure through one settled mechanical defect. What they do establish is that the system’s verified capability, operational use, and public representations did not line up. In a medical-testing business, that gap affects more than product marketing: it bears on whether a result can be relied on, whether a laboratory can deliver it consistently, and whether the service can responsibly scale.
What the record does—and does not—show
Official HHS records are most useful here for the analyzer’s limitations and the Walgreens rollout. The SEC’s release establishes its account of investor-related representations, fundraising, revenue, and the use of commercial analyzers in patient testing. The Justice Department’s case summary describes criminal allegations and outcomes. Taken together, these sources explain why the technology story and the legal story overlap, while remaining distinct.
They do not provide a complete independent scientific postmortem of the underlying laboratory mechanics. Without such evidence, attributing the problems to one specific mechanism or assigning a universal error rate would go beyond what these official summaries establish. The evidence supports a clear answer without that speculation: Theranos promoted a system whose claimed scope and advantages outstripped the proprietary analyzer’s documented performance and its role in actual patient testing.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
